+

WO2003046564A3 - Protein biopolymer markers predictive of alzheimers disease - Google Patents

Protein biopolymer markers predictive of alzheimers disease Download PDF

Info

Publication number
WO2003046564A3
WO2003046564A3 PCT/CA2002/001639 CA0201639W WO03046564A3 WO 2003046564 A3 WO2003046564 A3 WO 2003046564A3 CA 0201639 W CA0201639 W CA 0201639W WO 03046564 A3 WO03046564 A3 WO 03046564A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimers disease
absence
ability
biopolymer markers
Prior art date
Application number
PCT/CA2002/001639
Other languages
French (fr)
Other versions
WO2003046564A2 (en
Inventor
George Jackowski
John Marshall
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Priority to JP2003547952A priority Critical patent/JP2005510720A/en
Priority to AU2002335963A priority patent/AU2002335963A1/en
Publication of WO2003046564A2 publication Critical patent/WO2003046564A2/en
Publication of WO2003046564A3 publication Critical patent/WO2003046564A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
PCT/CA2002/001639 2001-11-23 2002-10-31 Protein biopolymer markers predictive of alzheimers disease WO2003046564A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2003547952A JP2005510720A (en) 2001-11-23 2002-10-31 Protein biopolymer markers that predict Alzheimer's disease
AU2002335963A AU2002335963A1 (en) 2001-11-23 2002-10-31 Protein biopolymer markers predictive of alzheimers disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99329801A 2001-11-23 2001-11-23
US09/993,298 2001-11-23

Publications (2)

Publication Number Publication Date
WO2003046564A2 WO2003046564A2 (en) 2003-06-05
WO2003046564A3 true WO2003046564A3 (en) 2004-02-19

Family

ID=25539359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001639 WO2003046564A2 (en) 2001-11-23 2002-10-31 Protein biopolymer markers predictive of alzheimers disease

Country Status (3)

Country Link
JP (1) JP2005510720A (en)
AU (1) AU2002335963A1 (en)
WO (1) WO2003046564A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1668149A4 (en) * 2003-09-05 2007-01-03 Royal Women S Hospital MARKER FOR THE DIAGNOSIS OF OVARIAN CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018801A2 (en) * 1998-09-29 2000-04-06 Roenn Lars Christian B Ncam binding compounds
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001057275A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018801A2 (en) * 1998-09-29 2000-04-06 Roenn Lars Christian B Ncam binding compounds
WO2001005422A2 (en) * 1999-07-15 2001-01-25 Biomerieux Stelhys Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2001057275A2 (en) * 2000-02-04 2001-08-09 Aeomica, Inc. Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DING LI ET AL: "The cloning and characterization of a novel human diacylglycerol kinase, DGKiota", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 49, 4 December 1998 (1998-12-04), pages 32746 - 32752, XP001154741, ISSN: 0021-9258 *
HARRIS E ET AL: "GAIN-OF-FUNCTION MUTATIONS IN A HUMAN CALMODULIN-LIKE PROTEIN IDENTIFY RESIDUES CRITICAL FOR CALMODULIN ACTION IN YEAST", MOLECULAR AND GENERAL GENETICS, SPRINGER VERLAG, BERLIN,, DE, vol. 247, no. 2, 1995, pages 137 - 147, XP000887215, ISSN: 0026-8925 *
HEMPERLY J J ET AL: "Characterization of cDNA clones defining variant forms of human neural cell adhesion molecule N-CAM.", JOURNAL OF MOLECULAR NEUROSCIENCE: MN. UNITED STATES 1990, vol. 2, no. 2, 1990, pages 71 - 78, XP009020161, ISSN: 0895-8696 *
KRIEG P A ET AL: "Primary structure and developmental expression of a large cytoplasmic domain form of Xenopus laevis neural cell adhesion molecule (NCAM).", NUCLEIC ACIDS RESEARCH. ENGLAND 25 DEC 1989, vol. 17, no. 24, 25 December 1989 (1989-12-25), pages 10321 - 10335, XP001155781, ISSN: 0305-1048 *
SMITH FRANCES J D ET AL: "Cloning of human, murine, and marsupial keratin 7 and a survey of K7 expression in the mouse.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 297, no. 4, 4 October 2002 (2002-10-04), October 4, 2002, pages 818 - 827, XP001152981, ISSN: 0006-291X *
YANG F ET AL: "IDENTIFICATION AND CHARACTERIZATION OF HUMAN HAPTO GLOBIN COMPLEMENTARY DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 80, no. 19, 1983, 1983, pages 5875 - 5879, XP009020251, ISSN: 0027-8424 *
YASWEN ET AL: "Down-regulation of a calmodulin-related gene during transformation of human mammary epithelial cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, October 1990 (1990-10-01), pages 7360 - 7364, XP002116285, ISSN: 0027-8424 *
ZATLOUKAL KURT ET AL: "p62 is a common component of cytoplasmic inclusions in protein aggregation diseases.", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, no. 1, January 2002 (2002-01-01), January, 2002, pages 255 - 263, XP009012659, ISSN: 0002-9440 *

Also Published As

Publication number Publication date
AU2002335963A1 (en) 2003-06-10
JP2005510720A (en) 2005-04-21
WO2003046564A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2002088722A3 (en) Biopolymer marker having a molecular weight of 1350 daltons
WO2003046572A3 (en) Biopolymer markers predictive of alzheimers disease
WO2003046565A3 (en) Ig lambda biopolymer markers predictive of alzheimers disease
WO2003046001A3 (en) Protein biopolymer markers predictive of insulin resistance
WO2003046573A3 (en) Protein biopolymer markers predictive of insulin resistance
WO2002088742A3 (en) Biopolymer marker having a molecular weight of 2937 daltons
WO2002088726A3 (en) Biopolymer marker having a molecular weight of 1449 daltons
WO2003045991A3 (en) Complement c3 precursor biopolymer markers predictive of alzheimers disease
WO2003046005A3 (en) Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
WO2003046558A3 (en) Complement c3 precursor biopolymer markers predictive of type ii diabetes
WO2002088743A3 (en) Biopolymer marker having a molecular weight of 1097 daltons
WO2002088174A3 (en) Biopolymer marker having a molecular weight of 1865 daltons
WO2002088715A3 (en) Biopolymer marker having a molecular weight of 1465 daltons
WO2003046571A3 (en) Hp and apolipoprotein biopolymer markers predictive of alzheimers disease
WO2002088747A3 (en) Biopolymer marker having a molecular weight of 1845 daltons
WO2002088711A3 (en) Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2003054014A3 (en) Apolipoprotein biopolymer markers predictive of alzheimers disease
WO2003046564A3 (en) Protein biopolymer markers predictive of alzheimers disease
WO2003046570A3 (en) Glycoprotein and apolipoprotein biopolymer markers predictive of alzheimers disease
WO2003046004A3 (en) Macroglobulin biopolymer markers indicative of insulin resistance
WO2003045984A3 (en) Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
WO2002088719A3 (en) Biopolymer marker having a molecular weight of 1424 daltons
WO2003046566A3 (en) Pedf biopolymer markers predictive of alzheimers disease
WO2003046567A3 (en) Protein biopolymer markers predictive of alzheimers disease
WO2003045993A3 (en) Protein biopolymer markers predictive of type ii diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003547952

Country of ref document: JP

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载